Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04963543
Other study ID # DEJ475-E003
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 22, 2021
Est. completion date October 29, 2021

Study information

Verified date November 2021
Source Alcon Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the comfort of an ocular lubricant in symptomatic contact lens wearers. This study will be conducted in Canada.


Description:

The duration of individual participation is six days.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date October 29, 2021
Est. primary completion date October 29, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Is able to understand and sign an approved information consent letter; - Habitually wears daily disposable soft contact lenses in both eyes; - Is able to achieve 20/40 or better monocular VA with habitual contact lenses; - Has a pair of spectacles for vision correction. - Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: - Routinely sleeps in habitual contact lenses; - Has any known active ocular disease and/or infection; - Is pregnant or lactating; - Other protocol-defined exclusion criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
FID123238
Lubricant applied to the ocular surface

Locations

Country Name City State
Canada Alcon Investigative Site 6189 Waterloo Ontario

Sponsors (1)

Lead Sponsor Collaborator
Alcon Research

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comfort, collected for each eye A visual analogue scale will be used Up to Day 6
See also
  Status Clinical Trial Phase
Completed NCT04693429 - Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ Phase 1
Completed NCT01423773 - Ocular Comfort and OCT Observation of Post Lens Clearance and Ocular Tissue Compression N/A
Completed NCT00520260 - Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase Phase 4